ORPEA (ORP.PA) 6.71 -0.11 (-1.61%)
6.71 -0.11 (-1.61%)
FR0000184798 - Common Stock
Fundamental Rating
Overall ORP gets a fundamental rating of 2 out of 10. We evaluated ORP against 10 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of ORP have multiple concerns. ORP is valued correctly, but it does not seem to be growing.
Profitability
Profitability Rating
ORP has a Piotroski-F score of 4.00. This indicates an average health and profitability for ORP.
ORP has a Return On Assets of 0.33%. This is below the industry average of 2.27%. 100% of the industry peers outperform ORP.
ORP has a Return On Equity of 1.76%. This is below the industry average of 7.56%. 100% of the industry peers outperform ORP.
ORP's Profit Margin of 1.52% is worse than the rest of the industry. The industry average Profit Margin is 3.64%. 89% of the industry peers have a better Profit Margin.
VS Industry
ROA (0.33%) VS Industry: 0% outperformed.
0.33
7.24
ROE (1.76%) VS Industry: 0% outperformed.
1.76
18.67
Profit Margin (1.52%) VS Industry: 11% outperformed.
0.85
11.09
Valuation
Valuation Rating
With a Price/Earnings Ratio of 6.64, the valuation of ORP can be described as very cheap.
ORP's Price/Earning Ratio is rather cheap when compared to the industry average which is at 11.14. ORP is also cheaper than 100% of the companies in the same industry.
With a Forward Price/Earnings Ratio of 8.43, the valuation of ORP can be described as very reasonable.
With a price book ratio of 0.12, ORP is valued rather cheaply.
When comparing the price book ratio of ORP to the average industry price book ratio of 1.18, ORP is valued rather cheaply. ORP is also cheaper than 100% of the companies listed in the same industry.
Compared to an average industry Enterprise Value to EBITDA ratio of 8.60, ORP is valued more expensive than its industry peers. 100% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (6.64) VS Industry: 100% outperformed.
36.33
6.64
Price/Book (0.12) VS Industry: 100% outperformed.
3.38
0.12
Enterprise Value/ EBITDA (14.21) VS Industry: 0% outperformed.
14.21
3.36
Growth
Growth Rating
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
The Earnings Per Share is expected to grow by 2.62% on average over the next 5 years.
The Revenue has been growing slightly by 9.59% in the past year.
ORP shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 8.63% yearly.
ORP is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 5.00% yearly.
ORP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.67%.
The earnings per share for ORP have been decreasing by -27.02% on average. This is quite bad
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | -27.02% | -33.38% | -58.67% | -125.71% | -53.27% | -21.37% | 2.62% |
| Revenue | 8.63% | 7.92% | 9.59% | 9.42% | 7.16% | 7.28% | 5% |
Health
Health Rating
The Piotroski-F score of ORP is 4.00. This is a neutral score and indicates average health and profitability for ORP.
A Current Ratio of 0.75 indicates that ORP may have some problems paying its short term obligations.
When comparing the Current Ratio of ORP to the average industry Current Ratio of 1.34, ORP is less able to pay its short term obligations than its industry peers. 89% of its industry peers have a better Current Ratio.
ORP has a Quick Ratio of 0.75. This is a bad value and indicates that ORP is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Quick Ratio of ORP to the average industry Current Ratio of 0.97, ORP is less able to pay its short term obligations than its industry peers.
ORP has one of the worst Debt to Equity ratios in its industry. 100% of its industry peers require less debt for financing their operations.
Based on the Altman-Z score of 0.38, we must say that ORP is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 1.52, ORP is in worse financial state than most of its industry peers. 100% of its industry peers have a better Altman-Z score.
VS Industry
Debt/Equity (2.94) VS Industry: 0% outperformed.
2.94
0.04
Quick Ratio (0.74) VS Industry: 22% outperformed.
0.47
2.30
Current Ratio (0.75) VS Industry: 11% outperformed.
0.64
3.05
Altman-Z (0.38) VS Industry: 0% outperformed.
0.38
6.08
Dividend
Dividend Rating
ORP does not give a dividend.
ORPEA6.71
EPA:ORP (12/9/2022, 7:00:00 PM)-0.11 (-1.61%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Providers & Services | ||
| Earnings (Last) | N/A N/A | Earnings (Next) | N/A N/A |
| Ins Owners | N/A | Inst Owners | N/A |
| Market Cap | 433.66M | Analysts | 42.67 |
| PE | 6.64 | Fwd PE | 8.43 |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 0.1 | P/B | 0.12 |
| EV/EBITDA | 14.21 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -58.67% | EPS 3Y | -33.38% |
| EPS 5Y | -27.02% | EPS growth Q2Q | -363.17% |
| EPS Next Y | -125.71% | EPS Next 2Y | -53.27% |
| EPS Next 3Y | -21.37% | EPS Next 5Y | 2.62% |
| Revenue growth 1Y | 9.59% | Revenue growth 3Y | 7.92% |
| Revenue growth 5Y | 8.63% | Revenue growth Q2Q | 10.87% |
| Revenue Next Year | 9.42% | Revenue Next 2Y | 7.16% |
| Revenue Next 3Y | 7.28% | Revenue Next 5Y | 5% |
| Current Ratio | 0.75 | Quick Ratio | 0.74 |
| Altman-Z | 0.38 | F-Score | 4 |
| Debt/Equity | 2.94 | WACC | 1.37% |
| ROIC/WACC | 1.35 | ||
| ROA | 0.33% | ROE | 1.76% |
| ROICexgc | 1.85% | ROIC | 1.18% |
| PM | 1.52% | OM | 6.38% |
| Asset Turnover | 0.22 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the EuroNext
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the EuroNext
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the EuroNext
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the EuroNext